CAR-T Meeting 2022 | Using T-cell engager antibodies to treat chronic viral hepatitis B and HBV-associated HCC
Ulrike Protzer, MD, Technical University of Munich, Munich, Germany, summarizes the main findings of a study using bispecific T-cell engagers (BiTEs) to target chronic viral hepatitis B and hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC). Prof. Protzer explains that these constructs can bind the HBV surface antigen on infected hepatocytes and activate T-cells. The study showed that these BiTes had a potent anti-viral and anti-tumor activity in both cell cultures and mouse models. This interview took place at the EBMT-EHA 4th European CAR T-cell Meeting which was held virtually in 2022.
Disclosures
Share holder and board member of SCG Cell Therapy.
Ad hoc scientific advisor for AbbVie, Arbutus, Gilead, GSK, Johnson & Johnson, Roche, Sanofi, Sobi, and Vaccitech.
